Share This Author
The mechanism of thrombin-induced platelet factor 4 secretion.
Ulastructural examination of thrombin-treated platelets revealed vacuoles corresponding in size, shape, and time of occurrence to the large immunofluorescent masses of PF4, which appear to represent the ultrastructureural counterpart of the large PF4 masses.
Pharmacokinetics and Metabolism of the Prodrug DB289 (2,5-Bis[4-(N-methoxyamidino)phenyl]furan Monomaleate) in Rat and Monkey and Its Conversion to the Antiprotozoal/Antifungal Drug DB75…
- I. Midgley, K. Fitzpatrick, Kerri L. Trendler
- Biology, ChemistryDrug Metabolism and Disposition
- 1 June 2007
Together, prodrug and active metabolite accounted for less than 20% of the plasma radioactivity after an oral dose, but DB75 was the major radiochemical component in key organs such as brain and liver and was largely responsible for the persistence of 14C in the body.
Binding characteristics of anti-Rh0(D) antibodies to Rh0(D)-positive and Du red cells.
The results show that the number of antigen sites differ by a factor of 10 to 15 between the Rh0(D)-positive and Du red cells, but that the dissociation constants between anti-Rh0( D) and the Rh 0(D) and Du antigens are indistinguishable when studied by the two labeling methods and two different anti- Rh0 (D) antibodies.
In Vitro/in Vivo Correlation for 14C-Methylated Lysozyme Release from Poly(Ether-Ester) Microspheres
- R. van Dijkhuizen-Radersma, S. J. Wright, L. Taylor, B. John, K. de Groot, J. Bezemer
- Biology, ChemistryPharmaceutical Research
- 1 March 2004
The in vitro release in phosphate-buffered saline and the in vivo release in rats showed an excellent congruence independent of the release rate of 14C-methylated lysozyme from PEGT/PBT microspheres.
Interactions of platinum compounds with heterocyclic bases
- L. Taylor
- 1 June 1990
It is generally accepted that platinum antitumoar drugs bind, preferentially, to Guanine N7 in DNA. Thus the kinetics of formation and the energetics of dissociation of platinum-nitrogen bonding have…
Von Willebrand Factor Levels Do Not Increase with Age in Patients with Type 1 Von Willebrand Disease.
No significant increase in VWF:Ag levels with age was demonstrated, and it is possible that age-related effects on VWF levels will differ depending on the underlying factor(s) resulting in a lower VWF level.